Inclusion Criteria:

          -  Histologically or cytologically confirmed solid malignancy or lymphoma that is
             metastatic or unresectable, and for which standard curative or palliative measures do
             not exist, or are no longer effective;

          -  Biliary obstruction with a biliary drain or stent;

          -  Neurologically stable gliomas and brain metastases;

          -  ECOG performance status of 0, 1, or 2;

          -  adequate bone marrow function;

          -  adequate pancreatic function;

          -  adequate renal function;

          -  female patients with negative pregnancy test

        Exclusion Criteria:

          -  untreated esophageal varices; uncontrolled ascites;

          -  episodes of hepatic encephalopathy within the last 4 weeks;

          -  spinal cord compression; major surgery within 4 weeks prior to enrollment;

          -  radiation therapy within 2 weeks prior to enrollment;

          -  last anti-cancer treatment within 2 weeks prior to screening;

          -  previous high-dose chemotherapy requiring stem cell rescue;

          -  prior to irradiation to >25% of the bone marrow;

          -  gastrointestinal abnormalities;

          -  known prior or suspected hypersensitivity to lorlatinib or lorlatinib tablet;

          -  clinically significant bacterial, fungal or viral infections for non-liver cancer
             patients;

          -  clinically significant cardiovascular disease;

          -  uncontrolled hypertension; acute pancreatitis with predisposing characteristics;

          -  history of grade 3 or 4 interstitial fibrosis or interstitial lung disease;

          -  active hemoelysis or evidence of biliary sepsis;

          -  prior major gastrointestinal surgery;

          -  concurrent use of known strong CYP3A inhibitors, inducers and P-gp substrates with a
             narrow therapeutic index;

          -  concurrent use of CYP3A substrates with narrow therapeutic indices;

          -  prior treatment with lorlatinib; active bleeding disorder